1. Meaning of sponsor indemnification

In a clinical trial, the Sponsor is generally the pharmaceutical company, institution, or other entity responsible for initiating/managing the study.

An indemnification clause is a contractual promise under which one party agrees to protect another party against specified losses, claims, damages, liabilities, legal expenses, etc.

Under Section 124 of the Indian Contract Act, 1872, a contract of indemnity is a contract by which one party promises to save another from loss caused by the conduct of the promisor or another person.

For example:

Sponsor agrees to indemnify the hospital/investigator against claims, damages, costs and expenses arising from the clinical trial, except to the extent caused by the hospital's or investigator's negligence, wilful misconduct, or breach of the protocol.

The exception is extremely important. It determines who ultimately bears the malpractice risk.

2. Sponsor indemnification is different from malpractice liability

There are actually two separate legal questions:

A. Who is legally liable to the injured patient?

This is determined by tort law, consumer law, clinical-trial regulations and other applicable law.

B. Who must ultimately bear the financial loss between Sponsor, Investigator, Hospital and CRO?

This is often determined by the Clinical Trial Agreement (CTA) and its indemnification provisions.

Therefore, an indemnity clause does not necessarily eliminate the patient's right to sue the doctor/hospital/sponsor.

It may simply give one contracting party a right to recover its losses from another.

Example

Suppose:

Sponsor → Hospital → Principal Investigator → Patient

A patient suffers injury because the investigator negligently administers the investigational drug.

The patient may pursue the legally responsible parties.

Separately, the Sponsor and Hospital may have an agreement saying:

• Sponsor indemnifies Hospital for trial-related product liability;
• Hospital indemnifies Sponsor for investigator negligence;
• Sponsor does not indemnify Hospital for Hospital's own negligence.

The ultimate financial allocation can therefore be different from the patient's initial claim.

3. Indian Contract Act: Sections 124–125

The starting point is Sections 124 and 125 of the Indian Contract Act, 1872.

Section 124 defines indemnity.

Section 125 gives the indemnity-holder important rights when sued, including recovery of:

1. damages which he is compelled to pay;
2. qualifying litigation costs; and
3. qualifying amounts paid under a prudent or authorized compromise. 

Therefore, an indemnification clause in a CTA can potentially cover:

• compensation paid to a patient;
• settlement amounts;
• defence costs;
• lawyers' fees;
• court costs;
• regulatory expenses, depending upon wording;
• other losses expressly covered by the agreement.

But the exact wording of the indemnity is critical.

4. Special position in clinical trials

For clinical trials in India, the New Drugs and Clinical Trials Rules, 2019 (NDCTR) are particularly important. The rules contain specific provisions concerning compensation for clinical-trial-related injury or death.

The regulatory framework recognizes compensation in situations including injury/death connected with, among other things:

• adverse effects of the investigational product;
• deviation from the approved protocol;
• scientific misconduct;
• negligence by the investigator or sponsor;
• failure of the investigational product to provide the intended therapeutic effect;
• placebo-related circumstances;
• certain concomitant-medication effects; and
• specified injury to an unborn child.

The earlier regulatory provisions also expressly required the sponsor to undertake, before commencement of the trial, to provide compensation where the subject is entitled to compensation.

The current NDCTR framework contains formulas for determining compensation in clinical-trial-related death and injury. For death, the Seventh Schedule provides a formula based upon a base amount, age factor and risk factor.

CDSCO — New Drugs and Clinical Trials Rules

5. Does sponsor indemnification cover malpractice?

It depends upon the cause of the injury and the contractual wording.

A typical CTA may distinguish between:

Sponsor's responsibility

The Sponsor may accept responsibility for:

• injury caused by the investigational product;
• defects in the investigational product;
• protocol design;
• Sponsor's own negligence;
• Sponsor's breach of applicable law;
• Sponsor's failure to comply with regulatory obligations.

Investigator/Hospital responsibility

The Hospital or Investigator may retain responsibility for:

• medical negligence;
• failure to follow the approved protocol;
• negligent administration of treatment;
• failure to obtain proper informed consent;
• deviation from the protocol without justification;
• wilful misconduct;
• fraud;
• failure to follow applicable medical standards.

Consequently, “clinical-trial injury” and “medical malpractice” are not automatically synonymous.

6. Important distinction: product liability vs professional negligence

Consider two cases.

Case 1 — Defective investigational product

A patient receives the drug exactly according to the approved protocol.

The drug causes an unexpected injury despite proper administration.

This may principally raise Sponsor/product-related liability.

Case 2 — Negligent administration

The investigational drug should have been administered at 10 mg but the investigator/hospital administers 100 mg because of a medical error.

This is much more clearly a professional negligence/protocol-compliance issue.

The CTA might therefore say:

Sponsor indemnifies the Institution against claims arising from the Investigational Product, except to the extent caused by negligence, wilful misconduct or breach of the protocol by the Institution or Investigator.

In Case 2, the Sponsor could argue that the contractual exception removes the claim from its indemnity.

7. Medical malpractice and hospital vicarious liability

Indian courts have repeatedly recognized that a hospital can be liable for negligence of doctors working within the hospital.

Savita Garg v. Director, National Heart Institute, (2004) 8 SCC 56

This is an important Supreme Court authority.

The Court emphasized that patients ordinarily approach a hospital based upon the hospital's reputation and expect the hospital to provide proper care. The Supreme Court recognized the hospital's responsibility for doctors engaged by it.

This principle is especially relevant where the hospital attempts to argue:

“The doctor was responsible, not the hospital.”

That argument does not automatically succeed.

8. Joseph v. Dr. George Moonjely

In Joseph alias Pappachan v. Dr. George Moonjely, the Kerala High Court dealt directly with hospital vicarious liability.

The Court held, in substance, that where a doctor employed by a hospital was negligent, the doctor was primarily liable and the hospital owner was vicariously liable for the doctor's negligence.

The reasoning is important:

The hospital accepts patients and must provide reasonable care. It performs that obligation through its doctors and staff. Consequently, negligence by those staff members can result in liability for the hospital.

9. Hospital cannot necessarily escape liability because doctor is a consultant

This becomes particularly important in clinical trials.

A hospital might argue:

“The Principal Investigator is an independent consultant, so we aren't responsible.”

Indian case law does not make the question that simple.

In Savita Garg, the Supreme Court recognized responsibility of the hospital for medical services provided through doctors associated with it. Later decisions have applied the principle even where doctors are not straightforward permanent employees.

Recent Indian decisions continue to cite the principle that the distinction between “contract of service” and “contract for service” does not automatically absolve a hospital from responsibility for medical negligence occurring through doctors providing services at the hospital.

10. Jacob Mathew v. State of Punjab

Another foundational Supreme Court decision is:

Jacob Mathew v. State of Punjab, (2005) 6 SCC 1.

The Supreme Court explained that medical negligence must be assessed differently from ordinary negligence.

A doctor is not negligent merely because:

• the treatment failed;
• the patient died;
• another treatment might have produced a better result; or
• an error of judgment occurred.

The question is whether the professional failed to exercise the reasonable competence expected in the circumstances.

The Supreme Court has subsequently reaffirmed these principles.

This distinction matters enormously in sponsor indemnification disputes.

Bad outcome ≠ automatically malpractice.

There must be a legally sufficient basis for negligence.

11. Maharaja Agrasen Hospital v. Master Rishabh Sharma

A particularly useful Supreme Court authority is:

Maharaja Agrasen Hospital & Ors. v. Master Rishabh Sharma & Ors., Civil Appeal No. 6619 of 2016, decided 16 December 2019.

The case is significant because the Supreme Court discussed both:

• medical negligence; and
• vicarious liability of hospitals.

The principle is that hospitals can be held responsible for negligence of doctors engaged or empaneled to provide medical care. The hospital cannot simply avoid responsibility by pointing to the individual doctor. This authority continues to be relied upon in subsequent decisions.

12. Direct liability vs vicarious liability

There are two important forms of hospital responsibility.

Vicarious liability

Hospital is liable because its doctor/staff member committed negligence in the course of providing hospital services.

Direct liability

Hospital itself was negligent.

For example:

• inadequate systems;
• inadequate supervision;
• incompetent staffing;
• inadequate emergency facilities;
• failure to maintain records;
• poor infection control;
• failure to follow required procedures;
• organisational failures.

Recent Indian decisions recognize that these concepts can operate separately.

This is important when drafting an indemnity clause because a Sponsor may want the hospital to indemnify it for both individual investigator negligence and institutional negligence.

13. What should a Sponsor indemnity clause contain?

A well-drafted clinical-trial indemnity normally addresses at least these questions:

14. Example of a balanced clause

A simplified illustration would be:

Sponsor Indemnification: The Sponsor shall indemnify and hold harmless the Institution, Principal Investigator and their respective officers and employees against third-party claims, damages, liabilities and reasonable legal expenses arising directly from injury or death of a Trial Subject to the extent caused by the Investigational Product, the Sponsor's negligence, or the Sponsor's breach of the Protocol or applicable law.

Institution/Investigator Indemnification: The Institution shall indemnify and hold harmless the Sponsor against claims, losses and reasonable legal expenses to the extent arising from the negligence, wilful misconduct, fraud, unauthorized deviation from the Protocol, or breach of applicable law by the Institution or Investigator.

Neither party shall be required to indemnify the other to the extent that the relevant loss was caused by the negligence or wilful misconduct of the party seeking indemnification.

That structure prevents a potentially unfair result where the Sponsor becomes responsible for every form of malpractice, including negligence entirely attributable to the investigator or hospital.

15. Can an indemnity clause protect a negligent doctor from the patient?

Generally, no—not automatically.

This is a very important distinction.

Suppose:

Doctor negligently injures patient → Hospital pays ₹20 lakh → Hospital invokes Sponsor indemnity.

The Sponsor may have to reimburse the Hospital if the CTA says the particular loss is covered.

But that does not necessarily mean:

“The doctor was not negligent.”

Nor does it necessarily prevent the patient from pursuing the doctor/hospital where the law permits it.

Indemnification reallocates financial risk between contracting parties; it does not automatically erase the underlying tort/negligence.

16. Sponsor vs CRO vs Investigator

In a modern clinical trial there may be four major parties:

Sponsor → CRO → Institution/Hospital → Investigator

The contract should distinguish their responsibilities.

Sponsor

Usually responsible for:

• trial design;
• investigational product;
• regulatory sponsorship;
• pharmacovigilance;
• Sponsor-controlled protocol issues;
• compensation obligations imposed by clinical-trial regulations.

CRO

Potentially responsible for:

• delegated trial-management functions;
• monitoring;
• data management;
• Sponsor-delegated regulatory functions.

Hospital/Institution

Potentially responsible for:

• facilities;
• staff;
• patient care;
• institutional procedures;
• investigator supervision;
• hospital negligence.

Investigator

Potentially responsible for:

• clinical decisions;
• patient management;
• informed consent;
• protocol compliance;
• accurate medical records;
• reporting adverse events;
• professional standard of care.

The indemnity should correspond to the actual allocation of responsibilities.

17. Why the words “arising out of” are dangerous

Consider two clauses:

Broad

Sponsor shall indemnify against all claims arising out of the clinical trial.

This could potentially be interpreted very broadly.

Narrower

Sponsor shall indemnify against claims arising directly from injury caused by the Investigational Product, except to the extent caused by negligence, wilful misconduct or breach of protocol by the Institution or Investigator.

The second provision allocates risk much more precisely.

Therefore, in reviewing a CTA, one should carefully examine:

“arising out of”

versus

“to the extent caused by”

versus

“directly caused by.”

Those words can materially change the financial exposure.

18. Malpractice insurance vs indemnification

These are also different.

Insurance

A third-party insurer assumes specified risks in exchange for premium.

Indemnification

One contracting party agrees to reimburse another party for specified losses.

A Sponsor might therefore require:

Institution shall maintain professional indemnity/malpractice insurance of ₹X crore.

And separately:

Sponsor shall indemnify Institution for specified clinical-trial risks.

Having insurance does not automatically make the indemnity clause unnecessary.

The CTA should ideally state:

• minimum insurance limits;
• whether Sponsor is an additional insured;
• whether claims-made or occurrence coverage applies;
• who pays deductibles;
• whether coverage continues after trial completion;
• whether “tail” coverage is required.

19. Key case-law principles

20. The central legal principle

The easiest way to remember the entire subject is:

Malpractice liability and indemnification are not the same thing.

Malpractice liability asks:

“Who is legally responsible for the patient's injury?”

Indemnification asks:

“As between Sponsor, Hospital, Investigator and CRO, who ultimately bears the financial consequences?”

In a clinical trial in India, the answer must be determined by combining:

NDCTR 2019 + Contract Act + CTA wording + medical-negligence law + hospital vicarious liability + applicable insurance arrangements.

The NDCTR framework is particularly significant because clinical-trial-related injury/death has a specific regulatory compensation mechanism, including circumstances involving investigator/sponsor negligence and prescribed compensation methodology.

Official CDSCO Clinical Trials resources

Important: This is an educational explanation of Indian law, not a legal opinion on a particular CTA or malpractice claim. For an actual indemnity clause, the precise wording, trial type, parties, and applicable law can change the analysis substantially.